NASDAQ:KALA - Kala Pharmaceuticals Stock Price, Forecast & News

Kala Pharmaceuticals' stock was trading at $7.63 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, KALA shares have decreased by 2.9% and is now trading at $7.41. View which stocks have been mosted impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kala Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kala Pharmaceuticals.

Kala Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Kala Pharmaceuticals.

Kala Pharmaceuticals Inc (NASDAQ:KALA) posted its quarterly earnings results on Wednesday, February, 12th. The company reported ($0.63) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.60) by $0.03. The company had revenue of $1.18 million for the quarter, compared to analyst estimates of $2.92 million. Kala Pharmaceuticals had a negative net margin of 1,553.29% and a negative return on equity of 173.83%. View Kala Pharmaceuticals' earnings history.

4 brokerages have issued 1 year target prices for Kala Pharmaceuticals' stock. Their forecasts range from $13.00 to $34.00. On average, they expect Kala Pharmaceuticals' stock price to reach $19.50 in the next twelve months. This suggests a possible upside of 163.2% from the stock's current price. View analysts' price targets for Kala Pharmaceuticals.

Headlines about KALA stock have been trending somewhat negative recently, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Kala Pharmaceuticals earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutKala Pharmaceuticals.

Kala Pharmaceuticals saw a increase in short interest in March. As of March 13th, there was short interest totaling 7,001,400 shares, an increase of 28.2% from the February 27th total of 5,460,000 shares. Based on an average daily volume of 2,339,000 shares, the short-interest ratio is currently 3.0 days. Approximately 23.5% of the company's shares are short sold. View Kala Pharmaceuticals' Current Options Chain.

Some companies that are related to Kala Pharmaceuticals include Innoviva (INVA), ZEALAND PHARMA/S (ZEAL), Ligand Pharmaceuticals (LGND), TG Therapeutics (TGTX), Zogenix (ZGNX), Madrigal Pharmaceuticals (MDGL), I-Mab (ARQT), Heron Therapeutics (HRTX), NextCure (NXTC), Akebia Therapeutics (AKBA), Esperion Therapeutics (ESPR), Opko Health (OPK), Enanta Pharmaceuticals (ENTA), Amneal Pharmaceuticals (AMRX) and Intra-Cellular Therapies (ITCI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kala Pharmaceuticals investors own include Amarin (AMRN), Bristol-Myers Squibb (BMY), Exelixis (EXEL), NVIDIA (NVDA), SCYNEXIS (SCYX), AbbVie (ABBV), Agile Therapeutics (AGRX), Gilead Sciences (GILD), Micron Technology (MU) and Sorrento Therapeutics (SRNE).

(KALA) raised $90 million in an IPO on Thursday, July 20th 2017. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.

Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA."

Kala Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Banco Bilbao Vizcaya Argentaria S.A. (4.06%), Sofinnova Investments Inc. (1.92%), Polaris Venture Management Co. V L.L.C. (1.64%), Alyeska Investment Group L.P. (1.27%), State Street Corp (1.05%) and Geode Capital Management LLC (0.92%). Company insiders that own Kala Pharmaceuticals stock include Gregory Grunberg, Howard B Rosen, Ra Capital Healthcare Fund Lp, Rajeev M Shah and Todd Bazemore. View institutional ownership trends for Kala Pharmaceuticals.

KALA stock was sold by a variety of institutional investors in the last quarter, including Polaris Venture Management Co. V L.L.C., Goldman Sachs Group Inc., Bank of New York Mellon Corp, Bank of America Corp DE, Alambic Investment Management L.P., and Group One Trading L.P.. View insider buying and selling activity for Kala Pharmaceuticals.

KALA stock was bought by a variety of institutional investors in the last quarter, including Banco Bilbao Vizcaya Argentaria S.A., Sofinnova Investments Inc., Nuveen Asset Management LLC, Wedbush Securities Inc., State Street Corp, Alyeska Investment Group L.P., Geode Capital Management LLC, and Virtu Financial LLC. Company insiders that have bought Kala Pharmaceuticals stock in the last two years include Gregory Grunberg, Howard B Rosen, Ra Capital Healthcare Fund Lp, Rajeev M Shah, and Todd Bazemore. View insider buying and selling activity for Kala Pharmaceuticals.

Shares of KALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of KALA stock can currently be purchased for approximately $7.41.

Kala Pharmaceuticals has a market capitalization of $285.80 million and generates $6.07 million in revenue each year. The company earns $-94,350,000.00 in net income (profit) each year or ($2.76) on an earnings per share basis. Kala Pharmaceuticals employs 130 workers across the globe. View additional information about Kala Pharmaceuticals.

The official website for Kala Pharmaceuticals is http://www.kalarx.com/.

Kala Pharmaceuticals' mailing address is 490 ARSENAL WAY SUITE 120, WATERTOWN MA, 02472. The company can be reached via phone at 781-996-5252 or via email at [email protected]